HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
Abstract
Authors
Giovany Orozco Leal Luke Vale Yemi Oluboyede Andrew Bryant Christopher Weetman Ciara Kennedy David Kavanagh Edwin Wong Janet Lecouturier Leonard Woodward Neil Sheerin Sally Johnson Sarah Dunn Thomas Chadwick Victoria Brocklebank